Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 1.65%
- Poor long term growth as Net Sales has grown by an annual rate of 0.62% and Operating profit at -222.28% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
The company has declared Negative results for the last 7 consecutive quarters
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,292 Million (Small Cap)
NA (Loss Making)
NA
0.15%
0.36
-10.97%
1.30
Revenue and Profits:
Net Sales:
241 Million
(Quarterly Results - Sep 2025)
Net Profit:
-19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.83%
0%
-3.83%
6 Months
-21.22%
0%
-21.22%
1 Year
-24.9%
0%
-24.9%
2 Years
-1.0%
0%
-1.0%
3 Years
-3.16%
0%
-3.16%
4 Years
-1.02%
0%
-1.02%
5 Years
30.56%
0%
30.56%
Shandong Sito Bio-technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.62%
EBIT Growth (5y)
-222.28%
EBIT to Interest (avg)
-0.06
Debt to EBITDA (avg)
5.40
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.40
Tax Ratio
2.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.65%
ROE (avg)
1.52%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.39
EV to EBIT
-18.63
EV to EBITDA
1111.82
EV to Capital Employed
1.30
EV to Sales
3.43
PEG Ratio
NA
Dividend Yield
0.13%
ROCE (Latest)
-6.96%
ROE (Latest)
-9.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
241.40
198.40
21.67%
Operating Profit (PBDIT) excl Other Income
-17.00
47.20
-136.02%
Interest
6.30
6.20
1.61%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.30
0.20
-9,750.00%
Operating Profit Margin (Excl OI)
-70.60%
21.60%
-9.22%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 21.67% vs -23.57% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -9,750.00% vs -80.00% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
967.20
1,276.20
-24.21%
Operating Profit (PBDIT) excl Other Income
25.90
171.20
-84.87%
Interest
35.20
40.90
-13.94%
Exceptional Items
0.10
-0.20
150.00%
Consolidate Net Profit
-101.30
48.50
-308.87%
Operating Profit Margin (Excl OI)
-94.80%
48.40%
-14.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -24.21% vs -2.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -308.87% vs 14.12% in Dec 2023
About Shandong Sito Bio-technology Co., Ltd. 
Shandong Sito Bio-technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






